Depression. PTSD. Alcohol use. Anxiety. Creativity. Trauma. Neuroplasticity. Healing.
Those are some pretty big words to be associated with a little mushroom.
Yet conversations about psilocybin, psychedelic-assisted therapy, microdosing and plant medicine have moved far beyond counterculture. Researchers, universities, healthcare professionals, veterans' organizations and people searching for different approaches to mental wellness are asking serious questions about psychedelics.
And perhaps the most important question isn't:
“Should I try mushrooms?”
It's:
“Where can I get trustworthy education about what we're actually learning?”
That's the conversation we're interested in having at 3-21 No Kiddin’ Recovery Playground in Naugatuck, Connecticut.
What is psilocybin?
Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. Once consumed, the body converts psilocybin into psilocin, which interacts strongly with serotonin receptors in the brain.
Researchers are studying how psychedelic compounds may affect mood, perception, cognition and neuroplasticity — the brain's ability to change, adapt and form new connections. NIH has highlighted research investigating how psychedelics may promote changes in neural connections and why that could matter in conditions such as treatment-resistant depression.
That's one reason this field has attracted so much scientific interest.
But it's important to understand that “psychedelics,” “psilocybin therapy,” and “microdosing” aren't interchangeable terms.
What is microdosing?
Microdosing generally refers to taking a very small amount of a psychedelic substance — an amount intended not to produce the full perceptual effects associated with a conventional psychedelic dose.
People report exploring microdosing for reasons including mood, stress, creativity, focus and general well-being.
But here's where education becomes extremely important:
Anecdotal enthusiasm has moved faster than clinical evidence.
The National Center for Complementary and Integrative Health notes that people use microdoses believing they may improve depression, stress, productivity or pain, but says it is not currently clear whether microdosing is safe or effective. A recent systematic review similarly concluded that the therapeutic efficacy of low-dose psilocybin remains unclear and requires more research.
So when you see a headline saying “psilocybin helps depression,” that does not automatically mean scientists have demonstrated that taking tiny doses at home treats depression.
That's exactly the kind of distinction people deserve to understand.
What does the research say about psilocybin and depression?
This is where the science gets particularly interesting.
Clinical research into psilocybin-assisted therapy for depression has produced promising results. NCCIH reports a growing body of evidence suggesting that psilocybin combined with psychological support may help depression in the short and medium term. It also notes that the FDA previously granted breakthrough-therapy designation to psilocybin-assisted psychotherapy programs being investigated for treatment-resistant depression and major depressive disorder.
A 2025 systematic review and meta-analysis of randomized controlled trials found that psilocybin-assisted therapy produced greater reductions in depressive symptoms than comparator interventions, although adverse effects such as headache and dizziness were more common.
Another 2025 review of randomized trials found an overall benefit but raised important cautions: studies were relatively small, results varied, blinding psychedelics is inherently difficult, and better-controlled studies tended to show smaller effects.
In other words:
Promising? Yes.
Settled science? No.
And that's a much more interesting conversation than either “mushrooms cure depression” or “it's all nonsense.”
What about PTSD and psychedelics?
PTSD is another area generating enormous interest, particularly among veterans and people who haven't received enough relief from existing treatments.
But again, different psychedelic compounds and different conditions have different levels of evidence.
The VA's National Center for PTSD says psychedelic-assisted therapies are being actively researched, while noting that published clinical evidence for psilocybin specifically as a PTSD treatment remains limited. The current VA/DoD clinical guideline says evidence is insufficient to recommend for or against psilocybin for PTSD.
That isn't the end of the story, though.
In August 2026, the Department of Veterans Affairs announced a new clinical trial investigating psilocybin for Veterans with treatment-resistant major depression, including Veterans who also have PTSD.
That's significant.
It doesn't prove psilocybin treats PTSD.
It shows that major medical institutions believe the questions are important enough to investigate rigorously.
What about psychedelics and alcohol use disorder?
This research is particularly fascinating for anyone interested in recovery.
A randomized clinical trial involving 93 adults with alcohol use disorder compared psychotherapy plus psilocybin with psychotherapy plus an active placebo. During the 32-week follow-up period, participants receiving psilocybin-assisted treatment had a significantly lower percentage of heavy-drinking days.
That doesn't mean psilocybin is a DIY treatment for alcohol addiction.
The intervention involved psilocybin administered alongside psychotherapy in a structured research setting — a very different situation from recreational psychedelic use or microdosing independently.
But it raises an extraordinary research question:
Could psychedelics eventually become another evidence-based tool for some people struggling with addiction?
Scientists are trying to answer it.
And considering how many people struggle when traditional approaches don't work for them, it's a question worth studying rather than dismissing.
Why are psychedelics being studied for such different conditions?
Depression, trauma and addiction sound like very different problems.
They are.
But researchers are interested in several mechanisms that may potentially overlap.
One is neuroplasticity.
Another is the possibility that psychedelic experiences, particularly when paired with professional psychological support, may temporarily alter deeply ingrained patterns of thought, emotion or behavior.
Think less:
“This substance makes someone happy.”
And more:
“Could there be a temporary window during which the brain becomes more flexible and therapeutic work happens differently?”
Researchers are still determining exactly what mechanisms matter and how much benefit comes from the psychedelic compound itself versus psychotherapy, expectation, environment and other factors. NIH describes neural plasticity as one important avenue researchers are investigating.
What are “set, setting and integration”?
If you've spent any time researching psychedelic-assisted therapy, you've probably encountered these words.
Set generally refers to a person's mindset going into an experience.
Setting refers to the physical and interpersonal environment.
Integration refers to making sense of an experience afterward and incorporating meaningful insights into everyday life.
That helps explain why legitimate clinical research looks very different from simply taking a substance.
In many psychedelic-assisted therapy studies, participants receive preparation beforehand, monitoring during the psychedelic session and therapeutic or integration support afterward. A recent JAMA Network Open analysis of psychedelic-assisted therapy specifically examined trials in which dosing sessions were embedded within preparation and integration therapy.
The experience isn't being studied in isolation.
The container matters.
Why is everybody suddenly talking about plant medicine?
Part of the answer is scientific.
Part is cultural.
And part is human.
People are asking different questions about mental health.
They're talking more openly about trauma. They're questioning the idea that one treatment model should work for everyone. They're interested in meditation, nervous-system regulation, functional wellness, recovery, spirituality and alternative approaches alongside — not necessarily instead of — conventional healthcare.
At the same time, psychedelic research has moved into respected scientific and medical institutions.
That creates an unusual moment where ancient practices, modern neuroscience, mental-health treatment and popular culture are colliding.
And whenever something moves that quickly, education becomes more important, not less.
There are risks too — and they belong in the conversation
“Natural” doesn't automatically mean safe.
Psilocybin can produce challenging psychological experiences and temporary physical effects. Psychedelics may be inappropriate or higher-risk for some people, including people with certain psychiatric histories or medication considerations. Researchers are still working to understand long-term risks, interactions, appropriate screening and which patients might — or might not — benefit.
NCCIH specifically cautions that psilocybin experiences can be unpredictable and that interactions with psychiatric medications are an active area of research.
That's another reason education should come before experimentation.
Good education isn't cheerleading.
It should be able to hold two ideas simultaneously:
There is legitimate reason to be excited about psychedelic research.
And:
There are legitimate reasons to be careful.
So where does microdosing fit into all of this?
Right now, somewhere between public fascination and developing science.
That's not an insult to microdosing.
It's an honest description of where the evidence stands.
Some people describe profound personal benefits from microdosing. Those experiences matter as human experiences, but they don't automatically establish medical effectiveness.
Meanwhile, controlled research continues.
That's why we believe the most responsible starting point isn't telling people what to take.
It's teaching people what questions to ask.
That's why we're hosting Microdosing 101 in Naugatuck, Connecticut
On Tuesday, October 28, from 6:30–8:30 PM, 3-21 No Kiddin’ Recovery Playground will host Microdosing 101, a private educational workshop led by Natasha Marie, a registered nurse with years of experience studying plant medicine who teaches workshops in South America.
The workshop will explore:
- What microdosing is — and isn't
- How psychedelics interact with the brain and body
- Why people are exploring microdosing
- Psilocybin and current mental-health research
- Depression and PTSD research
- Plant medicine and wellness
- Potential benefits and unanswered questions
- Safety and responsible considerations
- Personal experiences and insights
- Resources for continued learning
- An opportunity to ask questions without judgment
This is not a dosing event and no psychedelic substances are included, distributed or required.
It is an educational conversation.
Because adults deserve places where complicated subjects can be discussed intelligently without immediately being celebrated, condemned or shoved into a dark corner.
That's part of what a Recovery Playground should be.
Microdosing 101 — Event Details
Tuesday, October 28, 2026
6:30–8:30 PM
3-21 No Kiddin’ Recovery Playground
Naugatuck, Connecticut
$50 per person
Private event — advance registration required
Tickets are available at 321Nokiddin.com.
Come curious. Ask questions. Learn what the research actually says.
Educational disclaimer: This event and article are provided for educational purposes and are not medical advice, diagnosis or treatment. Psilocybin remains legally restricted in many jurisdictions. Nothing here is intended to encourage unlawful possession or use of controlled substances.